Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 12/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075882 | 0.90 | MAPT (0.39) | DHODHPLA2G2AMAPTMCHR1KMT2A | |
| SCHEMBL26075265 | 0.90 | ALOX5AP (0.40) | DHODHPLA2G2AMAPTMEN1KMT2A | |
| SCHEMBL26075234 | 0.89 | DHODH (0.44) | DHODHPLA2G2A | |
| SCHEMBL26075237 | 0.89 | PLA2G2A (0.44) | DHODHPLA2G2AMAPTKCNH2HRH3 | |
| SCHEMBL26075373 | 0.89 | HTR2B (0.40) | MAPTMCHR1TP53 | |
| SCHEMBL26075327 | 0.88 | SQOR (0.42) | DHODHPLA2G2AKCNH2HRH3MEN1 | |
| SCHEMBL26075339 | 0.87 | DHODH (0.39) | DHODHPLA2G2AKCNH2HRH3 | |
| SCHEMBL26075277 | 0.87 | PLA2G2A (0.42) | DHODHPLA2G2AMAPTKCNH2HRH3 | |
| SCHEMBL23590278 | 0.87 | DHODH (0.55) | DHODHPLA2G2AMEN1KMT2A | |
| SCHEMBL26075130 | 0.86 | HMOX1 (0.43) | DHODHPLA2G2AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | DHODH 1/4885PLA2G2A 1679/4885MAPT 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.